Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amoxicillin/clavulanate versus piperacillin/tazobactam for moderate diabetic foot infection
ACTRN12620000230954Phase 4Not yet recruiting
- Sponsor
- Gold Coast Hospital and Health Service
- Start
- Mar 2020
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetic foot infection (DFI) comparing Amoxicillin/clavulanate with Piperacillin/tazobactam (2 arms). Primary endpoint: Proportion of participants achieving treatment success. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
amoxicillin + clavulanatepiperacillin + tazobactam
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on ACTRN12620000230954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000230954.